News >

FDA Approves Vemurafenib for Rare Blood Cancer

Silas Inman @silasinman
Published: Monday, Nov 06, 2017

Richard Pazdur, MD
Richard Pazdur, MD
The FDA has approved vemurafenib (Zelboraf) as a treatment for patients with BRAF V600-mutated Erdheim-Chester disease (ECD), representing the first approved therapy for this rare blood disorder.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication